Cingulate CEO’s Bold Buy: 6,809 Shares and 5,447 Warrants Bought Amid 52‑Week High, Signaling Strong Insider Confidence.
CEO Shane Schaffer’s massive private‑placement buy in Cingulate signals strong insider confidence and may hint at upcoming clinical milestones.
4 minutes to read